10-Q quarterly report · filed Nov 9, 2026

Hims & Hers Health, Inc. (HIMS) Q3 2026 10-Q Quarterly Report

Short answer

Hims & Hers Health, Inc. (HIMS) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $890M (up 48.6% year over year) with net income of −$33M.

Q3 2026 key financials · XBRL

Revenue
$890M
+48.6% YoY · +18.2% QoQ
Net income
−$33M
−309.5% YoY · +61.7% QoQ
Operating margin
-7.4%
Gross margin
57.2%
EPS (diluted)
−$0.13
−316.7% YoY · +65.8% QoQ

Source: XBRL data from the Hims & Hers Health, Inc. (HIMS) Q3 2026 10-Q on SEC EDGAR. USD.

Hims & Hers Health, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $890.4M, up 49% YoY from $599.0M, driven by Rest of World revenue $233.3M, up 321%
  • Gross margin 57% vs 74% YoY; net loss $33.0M vs net income $15.8M
  • Hers strongest growth driver, 45% of U.S. revenue, versus approximately 40% YoY
  • Operating cash flow $65.4M vs $148.7M YoY; free cash flow $26.0M vs $79.4M
  • Near-term headwinds: gross margin below comparative periods from weight loss offerings, international acquisitions, and shorter shipping cadences

Risk Factors

  • New regulatory risk: testosterone therapy launched in 2026, with Schedule III products subject to DEA registration and controlled-substance requirements
  • Most material update: FDA directly named Hims & Hers in February 2026 GLP-1 statement, while HHS referred the company to DOJ
  • Legal exposure: FTC and state plaintiffs filed a July 2026 ROSCA and FTC Act complaint, with approximately $60 million accrued
  • Operational risk: branded GLP-1 transition may reduce demand and increase churn among customers using compounded alternatives
  • Financial risk: branded GLP-1 procurement costs may pressure margins, with limited ability to pass through price increases

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Hims & Hers Health, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.